Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator  by Knight, Bradley P et al.
Outcome of Patients
With Nonischemic Dilated
Cardiomyopathy and Unexplained Syncope
Treated With an Implantable Defibrillator
Bradley P. Knight, MD, Rajiva Goyal, MD, Frank Pelosi, MD, Matthew Flemming, MD,
Laura Horwood, RN, Fred Morady, MD, FACC, S. Adam Strickberger, MD, FACC
Ann Arbor, Michigan
OBJECTIVES The purpose of this study was to determine the outcome of patients with nonischemic dilated
cardiomyopathy, unexplained syncope and a negative electrophysiology test who are treated
with an implantable defibrillator.
BACKGROUND Patients with nonischemic cardiomyopathy and unexplained syncope may be at high risk for
sudden cardiac death, and they are sometimes treated with an implantable defibrillator.
METHODS This study prospectively determined the outcome of 14 consecutive patients who had a
nonischemic cardiomyopathy, unexplained syncope and a negative electrophysiology test and
who underwent defibrillator implantation (Syncope Group). Nineteen consecutive patients
with a nonischemic cardiomyopathy and a cardiac arrest who were treated with a defibrillator
(Arrest Group) served as a control group.
RESULTS Seven of 14 patients (50%) in the Syncope Group received appropriate shocks for ventricular
arrhythmias during a mean follow-up of 24 6 13 months, compared with 8 of 19 patients
(42%) in the Arrest Group during a mean follow-up of 45 6 40 months (p 5 0.1). The mean
duration from device implantation until the first appropriate shock was 32 6 7 months (95%
confidence interval [CI], 18 to 45 months) in the Syncope Group compared to 72 6 12
months (95% CI, 48 to 96 months) in the Arrest Group (p 5 0.1). Among patients who
received appropriate shocks, the mean time from defibrillator implantation to the first
appropriate shock was 10 6 14 months in the Syncope Group, compared with 48 6 47
months in the Arrest Group (p 5 0.06). Recurrent syncope was always associated with
ventricular tachyarrhythmias.
CONCLUSIONS The high incidence of appropriate defibrillator shocks and the association of recurrent
syncope with ventricular arrhythmias support the treatment of patients with nonischemic
cardiomyopathy, unexplained syncope and a negative electrophysiology test with an implant-
able defibrillator. (J Am Coll Cardiol 1999;33:1964–70) © 1999 by the American College of
Cardiology
Patients with nonischemic dilated cardiomyopathy (NICM)
and syncope have a one-year sudden death rate of up to 45%
(1–3). Because the value of electrophysiologic testing in
patients with NICM and unexplained syncope is uncertain
(3–6), defibrillator therapy is sometimes prescribed after a
See page 1971
negative electrophysiology test (7,8). However, little
follow-up data are available on the outcomes of these
patients. Therefore, the purpose of this study was to
determine the outcome of patients with NICM, unex-
plained syncope, and a negative electrophysiology test who
were treated with an implantable defibrillator.
METHODS
Patient characteristics. A total of 33 patients with a
clinical diagnosis of NICM were included in the study
population. Since 1993, all patients at our institution with
NICM and unexplained syncope who had a nondiagnostic
electrophysiology test have been treated with an implantable
defibrillator. During this time, 14 consecutive patients were
prospectively identified who had at least one episode of
unexplained syncope (mean number of syncopal episodes
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1.6 6 0.9; range 1 to 3) and a negative electrophysiology test
and who underwent implantation of a defibrillator (Syncope
Group). During the same time period, no patients with
NICM and unexplained syncope who were referred to our
institution for electrophysiologic testing had inducible ven-
tricular tachycardia. Twelve of the 14 patients with syncope
(86%) underwent cardiac catheterization, and 10 patients
had no obstructive coronary artery disease; 2 patients had a
single stenosis of .50%, diffuse myocardial dysfunction that
was disproportionate to the severity of coronary artery
disease, and no prior history of myocardial infarction. One
of the two patients who did not undergo cardiac catheter-
ization was 17 years old and had no history of myocardial
infarction. The remaining patient had severe global left
ventricular dysfunction and no inducible ischemia by do-
butamine stress echocardiography, consistent with NICM.
Using a prospective institutional database that includes all
defibrillator recipients, 19 consecutive patients who had a
cardiac arrest and underwent defibrillator implantation be-
tween 1988 and 1998 were retrospectively identified to serve
as a control group (Arrest Group). Documentation that a
cardiac catheterization was performed was available in 15
patients (79%), and in none of these patients was there
obstructive coronary disease. There were no identifiable
differences in the clinical characteristics of the patients in
the Syncope Group compared to the Arrest Group (Table 1).
Antiarrhythmic drug therapy was discontinued in all
patients after defibrillator implantation except for three
patients in the Arrest Group in whom amiodarone therapy
was continued at a dose of 200 mg/day. Angiotensin-
converting enzyme inhibitor therapy was prescribed at the
time of discharge in 13 (93%) of the patients in the Syncope
Group compared to 13 (68%) of the patients in the Arrest
Group (p 5 0.2). Beta-blockers were prescribed at the time
of discharge for one patient (7%) in the Syncope Group,
compared to four of the patients (21%) in the Arrest Group
(p 5 0.4).
Evaluation for syncope and cardiac arrest. Patients in the
Syncope Group were hospitalized after the episode of
syncope that preceded defibrillator implantation and were
included in this study only if the etiology of syncope
remained undetermined after a thorough evaluation. Each
patient underwent a complete history and physical exami-
nation, including carotid sinus massage, routine blood
measurements and electrocardiography. No patient had
nausea or fatigue associated with the syncopal episode to
suggest vasodepressor syndrome (9). Seven patients had a
negative head-up tilt-table test. In addition, each patient
underwent continuous electrocardiographic (ECG) moni-
toring for 4.9 6 4.0 days before defibrillator implantation,
and asymptomatic, nonsustained ventricular tachycardia was
present in nine (64%) patients. Twenty-four-hour ambula-
tory ECG monitoring was not performed. All patients in
the Syncope Group underwent complete electrophysiologic
testing. Standard assessments of sinus and atrioventricular
nodes and His-Purkinje function were performed, including
sinus node recovery time, atrioventricular node block cycle
length, atrioventricular node effective refractory period,
ventriculoatrial block cycle length, and His-ventricular con-
duction time. Programmed electrical stimulation of the
right ventricle was performed using a protocol consisting of
four extrastimuli at two right ventricular sites and three
basic drive cycle lengths, as previously described (10).
Programmed stimulation was repeated at one right ventric-
ular site during infusion of 2 mg/min of isoproterenol.
Patients were included in the Syncope Group if they had a
normal electrophysiology test or demonstrated nonspecific
abnormalities considered to be nondiagnostic (11).
Evaluation for patients who survived cardiac arrest in-
cluded hospitalization and a complete history and physical
examination. Potentially reversible causes of cardiac arrest
were excluded. Fifteen patients (79%) in the Arrest Group
underwent a complete electrophysiology test. Sustained
monomorphic ventricular tachycardia was inducible in two
of the patients (13%).
Implantable defibrillator systems. Each patient in the
Syncope Group underwent implantation of a nonthora-
cotomy defibrillator that provided stored R-R intervals or
intracardiac electrograms (Guidant, St. Paul, Minnesota;
models 1705, 1720, 1740, 1762 and 1763), or both. The
mean implant defibrillation energy requirement was 13 6 5
J, and there were no implant-related complications.
Twelve patients (63%) in the Arrest Group underwent
implantation of a defibrillator that provided stored R-R
intervals and/or intracardiac electrograms (Guidant, St.
Paul, Minnesota; models 1625, 1705, 1715, and 1720;
Medtronic, Minneapolis, Minnesota; models 7219, 7223;
St. Jude Medical, Sunnyvale, California; Ventritex models
V100 and 7223), and seven patients (37%) received a
Abbreviations and Acronyms
NICM 5 nonischemic dilated cardiomyopathy
NYHA 5 New York Heart Association
Table 1. Patients’ Characteristics
Clinical Characteristic
Syncope
Group
Arrest
Group p-Value
Number 14 19 —
Age (yrs) 53 6 16 52 6 13 NS
Gender (M/F) 9/5 11/8 NS
LVEF 0.26 6 0.11 0.21 6 0.10 NS
Chronic rhythm (SR/AF) 11/3 19/0 NS
ACEI therapy 93% 68% NS
Beta-blocker therapy 7% 21% NS
Amiodarone therapy 0% 16%* NS
*Daily amiodarone dose was 200 mg in each patient.
ACEI 5 angiotensin-converting enzyme inhibitor; AF 5 atrial fibrillation;
LVEF 5 left ventricular ejection fraction; NS 5 not significant; SR 5 sinus rhythm.
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non-event-recording defibrillator (Guidant; models 1500,
1520, 1550, and 1600). Four patients received an epicardial
lead system and 15 patients received a nonthoracotomy lead
system. The mean implant defibrillation energy requirement
was 15 6 8 J in the Arrest Group. Implantation was
complicated by a pneumothorax in one patient. Seven
patients underwent elective generator replacement during
follow-up for battery depletion.
Implantable defibrillator programming. In patients in the
Syncope Group, the defibrillator was programmed to a
one-zone device in 11 patients, with a tachycardia detection
rate cutoff of 180 6 11 beats/min. In the remaining three
patients, the defibrillator was programmed to a two-zone
device to allow for empiric antitachycardia pacing therapy in
the first zone, with a first zone rate cutoff of 180 6 18
beats/min and a second zone rate cutoff of 207 6 13
beats/min. Ventricular demand (VVI) pacing was pro-
grammed to 40 beats/min in 13 patients and 50 beats/min
in 1 patient. The percent of time patients received brady-
cardia pacing from the defibrillator was available in 10
patients and was reported in increments of 1%.
Among the patients in the Arrest Group, the defibrillator
was programmed to a one-zone device in 17 patients, with
a tachycardia detection rate cutoff of 174 6 9 beats/min. In
the remaining two patients, the defibrillator was pro-
grammed to a two-zone device, with a first zone rate cutoff
of 138 6 4 beats/min and a second zone rate cutoff of 175 6
7 beats/min, with empiric antitachycardia pacing pro-
grammed in the first zone. The VVI pacing was pro-
grammed to 40 beats/min in 12 patients, 50 beats/min in 1
patient and was not available for the remaining 6 patients.
Concomitant pacemaker therapy. Two patients in each
group were previously treated with a dedicated pacemaker in
addition to an implantable defibrillator 5.3 6 3.9 months
before defibrillator implantation. In addition, one patient in
the Syncope Group received a pacemaker for bradycardia-
dependent oversensing by the defibrillator (12), and one
patient in the Arrest Group received a pacemaker for carotid
sinus hypersensitivity after defibrillator implantation.
Follow-up. The duration of follow-up was calculated from
the time of defibrillator implantation. Patients were fol-
lowed in clinic every four months. Defibrillator function,
device therapy history, and occurrence of syncope or presyn-
cope were documented and evaluated during each clinic
visit. Surviving patients or their primary physicians were
contacted by telephone in May 1998 if they had not been
seen in the University of Michigan Defibrillator Clinic
within the previous three months. The medical records of all
patients who died during follow-up were reviewed.
Analysis of defibrillator therapies. Among the seven pa-
tients in the Arrest Group with non-event-recording im-
plantable defibrillators, an appropriate shock was defined as
one associated with syncope, presyncope, or a rate over 200
beats/min. Among the remaining 12 patients in the Arrest
Group, and for all patients in the Syncope Group, the stored
intracardiac electrograms or R-R intervals of all implantable
defibrillator events were reviewed. The rhythms that were
associated with defibrillator therapy were categorized as
sinus tachycardia, atrial fibrillation, or ventricular arrhyth-
mias, based on visual inspection of intracardiac electrograms
or analysis of the R-R intervals, a comparison with the
electrogram obtained during the baseline rhythm, and the
response to therapy (13). Monomorphic ventricular tachy-
cardia was defined as a regular tachycardia with an electro-
gram morphology that differed from the baseline rhythm
and was distinguished from atrial fibrillation by an R-R
interval variability of ,60 ms. Ventricular fibrillation and
polymorphic ventricular tachycardia were defined as irreg-
ular tachycardias with polymorphic electrogram morphol-
ogy. Appropriate defibrillator shocks were defined as shocks
delivered for a ventricular tachyarrhythmia.
Statistical analysis. Continuous variables are expressed as
mean 6 SD and were compared using the Student t test or
Mann-Whitney U nonparametric test, as appropriate.
Nominal variables were compared using the chi-square or
Fisher exact test, as appropriate. Kaplan-Meier survival
curves were constructed for each patient group to express
overall morality and the time from defibrillator implantation
to first appropriate shock. Patients who underwent cardiac
transplantation were censored from the survival analysis at
the time of the operation. A log-rank test was used to
compare Kaplan-Meier curves. Univariate analysis was per-
formed on clinical variables to determine predictors of
appropriate defibrillator shocks. A p value of ,0.05 was
considered statistically significant.
RESULTS
Appropriate defibrillatory therapies. Appropriate defi-
brillator shocks occurred in 7 of 14 patients (50%) during a
mean follow-up of 24 6 13 months in the Syncope Group
compared with 8 of 19 patients (42%) during a mean
follow-up of 47 6 41 months in the Arrest Group (Fig. 1;
p 5 0.1). Using Kaplan-Meier analysis, the mean duration
from device implantation until the first appropriate shock
was 32 6 7 months (95% CI, 18 to 45 months) in the
Syncope Group compared to 72 6 12 months (95% CI, 48
to 96 months) in the Arrest Group (p 5 0.1). The actuarial
incidence of appropriate shocks at one and two years was
36% and 43%, respectively, in the Syncope Group, and 10%
and 21%, respectively, in the Arrest Group.
Among patients who received appropriate shocks, the
mean time from defibrillator implantation to the first
appropriate shock was 10 6 14 months in the Syncope
Group, compared with 48 6 47 months in the Arrest
Group (p 5 0.06). The rate of the ventricular arrhythmia
for the first appropriate shock was 257 6 39 beats/min in
the Syncope Group, compared with 258 6 46 beats/min in
the Arrest Group (p 5 1.0). One patient each group
received .10 shocks during follow up. Among the remain-
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ing patients who received appropriate shocks, there was a
total of 2.2 6 1.5 appropriate shocks in the Syncope Group,
compared with 1.4 6 0.8 shocks in the Arrest Group (p 5
0.3). The mean duration of the ventricular arrhythmia
resulting in a defibrillator shock was 11.8 6 0.5 s in the
Syncope Group. No patient in either group received anti-
tachycardia pacing for a ventricular arrhythmia.
Seven patients (50%) in the Syncope Group received
shocks for atrial fibrillation or sinus tachycardia, compared
to four patients (21%) in the Arrest Group (p 5 0.08). One
patient in the Arrest Group received inappropriate shocks
due to an epicardial sensing lead fracture and underwent
endocardial lead placement. One of the two patients in each
group who had a pacemaker before defibrillator implanta-
tion received appropriate shocks.
Five of the eight patients in the Arrest Group who
received appropriate shocks had initially undergone implan-
tation of a device without R-R intervals or stored electro-
grams. However, three of the five patients underwent
generator replacement with a device that had retrievable
R-R intervals before they received their first appropriate
shock. The remaining two patients had not undergone
generator replacement before their first shock but experi-
enced presyncope with the shock.
One patient in the Syncope Group was treated with
bradycardia pacing from the defibrillator for 9% of the time
after amiodarone therapy was initiated for ventricular tachy-
cardia. No other patient received bradycardia pacing for
more than 0.5% of the time during follow up.
Mortality. There was no significant difference in mortality
between the Syncope Group (4 of 14 patients, 28%) and the
Arrest Group (6 of 19 patients, 32%; p 5 0.8; Fig. 2). Using
Kaplan-Meier analysis, the mean survival time was 40 6 5
months (95% CI, 30 to 50 months) in the Syncope Group
compared with 86 6 13 months (95% CI, 61 to 111
months) in the Arrest Group (p 5 0.08). In the Syncope
Group, three of the four patients died of progressive
congestive heart failure 6.3 6 2.1 months after defibrillator
implantation. The other patient died suddenly in an emer-
gency department 36 months following implantation. In the
Arrest Group, three of the six patients died of progressive
congestive heart failure 12.3 6 17.1 months after defibril-
lator implantation. A fourth patient died of asystole in an
emergency department 17 months post-implantation and
three hours after receiving three shocks for atrial fibrillation.
The remaining two patients in the Arrest Group died of
unclear reasons 9 and 13 months after defibrillator implan-
tation. Two of the four patients in the Syncope group who
died received at least one appropriate defibrillator shock
three and five months before death, compared with none of
the six patients in the Arrest Group who died. One patient
in the Syncope Group underwent successful cardiac trans-
plantation 14 months after defibrillator implantation and 2
months after receiving two appropriate shocks. One patient
in the Arrest Group underwent cardiac transplantation 19
months after implantation and 7 months after receiving an
appropriate shock.
Recurrent syncope. Among patients in the Syncope
Group, an appropriate shock associated with syncope or
presyncope occurred in one and four patients, respectively.
One of the four patients who had presyncope associated
with a shock also had episodes of presyncope that were not
associated with device therapy. In this patient, a continuous
loop recorder correlated the episodes with up to 18 beats of
nonsustained monomorphic ventricular tachycardia at a rate
of 200 beats/min. An additional patient had unexplained
Figure 1. Kaplan-Meier survival curves depicting freedom from
appropriate defibrillator shocks for patients in the Syncope Group
(solid line) compared to the Arrest Group (dotted line). Each
vertical mark represents a censored event.
Figure 2. Kaplan-Meier survival curves depicting overall mortality
for patients in the Syncope Group (solid line) compared to the
Arrest Group (dotted line). Each vertical mark represents a
censored event.
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presyncope three years after defibrillator implantation that
was not associated with a shock.
Patients with syncope and appropriate defibrillator
shocks. Among patients in the Syncope Group, those who
received appropriate shocks had a lower left ventricular
ejection fraction (0.20 6 0.07 vs. 0.31 6 0.12; p 5 0.04)
and a worse New York Heart Association (NYHA) func-
tional class (2.7 6 0.8 vs. 1.4 6 0.5; p 5 0.02) compared to
patients who did not receive appropriate shocks (Table 2).
None of the three patients with an ejection fraction .35%
received an appropriate shock during follow-up. However,
no cutoff point could be identified that distinguished the
patients who received shocks from those who did not. All
six patients with NYHA class III heart failure received
appropriate defibrillator shocks. The remaining patient who
received appropriate shocks had NYHA class I symptoms.
There were no significant differences in the clinical charac-
teristics among patients in the Arrest Group who did and
did not receive appropriate shocks.
DISCUSSION
Main findings. This study found that 50% of patients with
NICM, unexplained syncope, and a negative electrophysi-
ology test who were treated with an implantable defibrillator
received appropriate defibrillator shocks for ventricular ar-
rhythmias during a mean follow-up of two years, and that
recurrent syncope and presyncope were primarily due to
ventricular tachyarrhythmias. The incidence of appropriate
shocks was similar to patients with NICM and a history of
cardiac arrest.
Pacemaker therapy. An alternative treatment option to an
implantable defibrillator in patients with NICM, unex-
plained syncope, and a nondiagnostic electrophysiology test
includes empiric pacemaker therapy. Although a bradycar-
dia may be responsible for sudden death in some patients
with advanced heart failure (14), pacing therapy has not
been shown to improve survival (15). In the present study,
the implantable defibrillators in each patient in the Syncope
Group provided fixed-rate backup bradycardia pacing, yet
half of these patients still received defibrillator shocks for
ventricular arrhythmias. In addition, only one patient in the
Syncope Group received a significant amount of bradycardia
pacing. However, the possibility that brief episodes of
ventricular pacing therapy prevented recurrent syncope or
sudden death in some patients cannot be excluded.
Predictors of appropriate defibrillator shocks. The ability
to identify patients with NICM and unexplained syncope
who will receive appropriate shocks after defibrillator im-
plantation would be useful. All patients in the Syncope
Group with NYHA class III functional status prior to
defibrillator implantation received appropriate shocks dur-
ing follow-up. One patient with class I symptoms, however,
also received appropriate shocks. No patient in the Syncope
Group with an ejection fraction .35% received an appro-
priate shock. However, only 3 of the 14 patients (21%) had
an ejection fraction .35% and there was no cutoff point to
differentiate patients who received appropriate shocks from
those who did not. Therefore, although it appears that
patients with more severe cardiomyopathy are more likely to
receive appropriate shocks, the usefulness of clinical char-
acteristics as predictors of appropriate defibrillator shocks
among patients with NICM and unexplained syncope may
be limited.
Prior studies. Electrophysiologic testing is frequently used
to determine the cause of syncope (11,16–19). However,
electrophysiologic testing may be less useful in selected
subgroups of patients, including patients with dilated car-
diomyopathy (3–6,11). The inability of electrophysiologic
testing to risk-stratify asymptomatic patients with dilated
cardiomyopathy (4–6), in contrast to patients with ischemic
cardiomyopathy (20), highlights the limitations of pro-
grammed electrical stimulation. For patients with NICM
who present with syncope, there are minimal data regarding
the use of electrophysiologic testing (3,11). A natural
history study of 99 patients with unexplained syncope and a
nondiagnostic electrophysiologic test included only 6 pa-
tients with dilated cardiomyopathy (11). A study of 60
patients with advanced heart failure and syncope included
33 patients (55%) with NICM, and found the one-year risk
of sudden death to be 45% irrespective of the etiology of
syncope (3). These results suggest that electrophysiologic
testing in patients with NICM has a low negative predictive
value.
Two studies of the outcome of patients with NICM
treated with an implantable defibrillator have been reported
(21,22). Each study included a limited number of patients
who presented with syncope. Ten patients in the study by
Fazio et al. (21) presented with syncope. However, each
patient had syncope that was documented to be due to
ventricular tachycardia, and only two of the patients were
Table 2. Clinical Characteristics of Patients in the Syncope
Group Who Did and Did Not Receive Appropriate
Defibrillator Shocks
Clinical
Characteristic
Patients With
Appropriate
Shocks
Patients Without
Appropriate
Shocks p-Value
Number 7 7 —
Age (yrs) 58 6 10 48 6 21 NS
Gender (M/F) 5/2 4/3 NS
LVEF 0.20 6 0.07 0.31 6 0.12 0.04
NYHA class 2.7 6 0.8 1.4 6 0.5 0.02
Rhythm (SR/AF) 4/3 7/0 NS
NSVT (yes/no) 6/1 3/4 NS
Syncopal episodes 1.6 6 0.8 1.6 6 1.1 NS
AF 5 atrial fibrillation; LVEF 5 left ventricular ejection fraction; NSVT 5
nonsustained ventricular tachycardia; NYHA 5 New York Heart Association; SR 5
sinus rhythm.
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noninducible at electrophysiology testing. Six of the 49
defibrillator recipients in the study by Grimm et al. (22)
presented with syncope. It was not reported if spontaneous
sustained ventricular tachycardia occurred in these patients.
In addition, the results of electrophysiology testing were not
specifically reported for the patients with syncope. The
actuarial incidence of shocks in the present study among
patients in the Syncope Group (45% at two years) was
comparable to the results of both Fazio et al. (21) (42% at 18
months) and the results of Grimm et al. (22) (49% at three
years).
Study limitations. A limitation of this study is the small
sample size. A second limitation is the uncertainty associ-
ated with categorizing a defibrillator shock as appropriate in
patients with devices that do not provide stored R-R
intervals or electrograms. However, all patients in the
Syncope Group initially had event-recording devices im-
planted compared to 63% of the patients in the Arrest
Group. Therefore, if the incidence of appropriate shocks
was overestimated, this was more likely to have occurred in
the Arrest Group.
Clinical implications. Recent practice guidelines from the
American College of Cardiology and the American Heart
Association do not consider syncope of undetermined cause
in the absence of inducible ventricular tachyarrhythmias to
be an indication for defibrillator implantation (23). The
present study does not prove that implantable defibrillators
reduce mortality in patients with NICM and unexplained
syncope. However, occurrences of syncope and presyncope
largely in association with ventricular arrhythmias, and the
similar incidence of appropriate shocks compared to pa-
tients with NICM and a previous cardiac arrest, support the
use of defibrillators in this setting. The benefit of defibril-
lators compared to antiarrhythmic drugs in patients with
documented life-threatening arrhythmias (24,25) and the
low risk associated with nonthoracotomy defibrillator im-
plantation (26,27) provide additional rationale for this
approach. Further study is required to determine the effect
of this approach on overall mortality and its cost-
effectiveness (28).
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